Evidence & concentration worksheet · Growth Hormone & Performance
CJC-1295 DAC 2 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
CJC-1295 DAC is a long-acting analogue of growth hormone-releasing hormone (GHRH). Its Drug Affinity Complex includes an albumin-binding modification intended to prolong exposure.[1]
FDA's 2024 review identified two different active moieties and at least five distinct CJC-1295-related bulk substances, including multiple DAC salts. Names, identifiers, certificates, and clinical citations were often inconsistent. Evidence cannot safely be transferred between DAC, no-DAC, free-base, acetate, and TFA forms.[1]
Benefits & side effects
FDA found only three published human studies, all in healthy adults, and no study in people with a disease or condition. No human effectiveness evidence established CJC-1295 DAC for growth hormone deficiency or another indication.[1]
People with complete growth hormone deficiency may not respond to a secretagogue in the way healthy volunteers do. Results from volunteers with an intact hypothalamic-pituitary axis therefore cannot be treated as treatment evidence.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA evaluation of CJC-1295-related bulk drug substances (2024)
- Journal of Clinical Endocrinology & Metabolism — Prolonged GH and IGF-1 secretion after CJC-1295 in healthy adults (2006)
- Journal of Clinical Endocrinology & Metabolism — Pulsatile GH secretion during continuous stimulation by CJC-1295 (2006)
- U.S. FDA — Bulk substances that may present significant compounding safety risks (2026)
- World Anti-Doping Agency — 2026 Prohibited List (2026)